AMRN - Amarin Corporation plc

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
2.96
-0.06 (-1.99%)
At close: 4:00PM EDT

2.96 -0.00 (-0.00%)
After hours: 4:47PM EDT

Stock chart is not supported by your current browser
Previous Close3.02
Open3.04
Bid2.92 x 36100
Ask3.01 x 3000
Day's Range2.93 - 3.05
52 Week Range2.35 - 4.60
Volume1,714,574
Avg. Volume2,716,970
Market Cap870.048M
Beta1.29
PE Ratio (TTM)N/A
EPS (TTM)-0.26
Earnings DateMay 4, 2017 - May 8, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.60
Trade prices are not sourced from all markets
  • Better Speculative Biotech Stock: Amarin Corporation vs. Geron Corporation
    Motley Fool2 days ago

    Better Speculative Biotech Stock: Amarin Corporation vs. Geron Corporation

    Amarin and Geron are both racing toward major binary events that could pay off for early shareholders in a big way.

  • Thomson Reuters StreetEvents3 days ago

    Edited Transcript of AMRN earnings conference call or presentation 1-Aug-18 11:30am GMT

    Q2 2018 Amarin Corporation PLC Earnings Call

  • This Small-Cap Biotech Is Poised for Eye-Popping Gains
    Motley Fool15 days ago

    This Small-Cap Biotech Is Poised for Eye-Popping Gains

    Vascepa's all-important cardiovascular-outcomes trial is less than two month's away from a top-line readout.

  • Associated Press17 days ago

    Amarin: 2Q Earnings Snapshot

    On a per-share basis, the Dublin-based company said it had a loss of 12 cents. Losses, adjusted for stock option expense, were 10 cents per share. The results did not meet Wall Street expectations. The ...

  • GlobeNewswire17 days ago

    Amarin Reports Second Quarter 2018 Financial Results and Provides Update on Operations

    REDUCE-IT™ Study On-Track for Reporting Top-Line Results by the End of September 2018. Management to Host Conference Call at 7:30 a.m. ET Today. BEDMINSTER, N.J., and DUBLIN, Ireland, Aug. 01, 2018-- Amarin ...

  • GlobeNewswire23 days ago

    Amarin Announces Approval for Vascepa® in United Arab Emirates

    BEDMINSTER, N.J. and DUBLIN, Ireland, July 26, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, along with its commercial partner, Biologix FZCo, a pioneer in the distribution of pharmaceutical and biological products in the Middle East and North Africa (MENA) region, today announced that United Arab Emirates (UAE) Ministry of Health and Prevention has approved Vascepa® (icosapent ethyl) capsules as a prescription medication for use as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (TG 500 mg/dL) hypertriglyceridemia in the UAE. This approval is a result of the collaborative effort by the parties since the start of their 2016 agreement to register and commercialize Vascepa in multiple countries in the MENA region.

  • GlobeNewswire25 days ago

    Amarin to Report Second Quarter 2018 Results and Host Conference Call on August 1, 2018

    Amarin Corporation plc (AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the company's second quarter 2018 financial results and provide an operational update on August 1 at 7:30 a.m. EDT. Investors and others should note that Amarin communicates with its investors and the public using the company website (http://www.amarincorp.com/), the investor relations website (http://investor.amarincorp.com/), including but not limited to investor presentations and investor FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts.  The information that Amarin posts on these channels and websites could be deemed to be material information.  As a result, Amarin encourages investors, the media, and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis.  This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels.  The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

  • 3 Top Biotech Stocks to Buy Right Now
    Motley Foollast month

    3 Top Biotech Stocks to Buy Right Now

    This could be a good time to add a profit-friendly play, a clinical-stage upstart, and a make-or-break biotech to your portfolio.

  • Is Now the Perfect Time to Buy Amarin Corporation Stock?
    Motley Foollast month

    Is Now the Perfect Time to Buy Amarin Corporation Stock?

    Amarin's next major clinical catalyst is close at hand, but investors may want to stick to the sidelines with this high-risk stock.

  • ACCESSWIRE2 months ago

    Breakfast Technical Briefing on Amarin and Three Other Additional Biotech Stocks

    On Friday, June 29, 2018, US markets saw broad based gains with six out of nine sectors finishing the trading sessions in green. All you have to do is sign up today for this free limited time offer by clicking the link below.

  • Why Amarin Rose ~10% Yesterday
    Market Realist2 months ago

    Why Amarin Rose ~10% Yesterday

    On June 28, Amarin (AMRN) stock rose ~10% after the company announced the occurrence of the last patient visit in its REDUCE-IT study, a long-term cardiovascular outcome study, of its fish oil product Vascepa. Amarin’s Vascepa was approved by the FDA (U.S. Food and Drug Administration) in 2012. Despite the large number of Americans having high triglyceride levels and the potentially high patient base for Vascepa, the company is still seeing lower-than-expected sales from the pill.

  • Why Amarin Corporation Zoomed 10% Higher Today
    Motley Fool2 months ago

    Why Amarin Corporation Zoomed 10% Higher Today

    Big news is fast-approaching for its one and only commercial-stage drug.

  • GlobeNewswire2 months ago

    Amarin Reports Last Patient Study Visit Has Occurred, an Important Step Towards Completion of REDUCE-IT™ Cardiovascular Outcomes Study

    Amarin Corporation plc (AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that the last patient study visit has occurred in its potential landmark cardiovascular outcomes study, REDUCE-IT™.  The company also reiterated that it anticipates having top-line results for this important study reported before the end of Q3 2018. As is typical of large, multi-national, long-term outcomes studies, the final steps preceding REDUCE-IT completion include resolving remaining queries to contribute to a robust and accurate database.  This “cleaning” process is characteristically intensive and time consuming.

  • GlobeNewswire2 months ago

    Real-World Data Supports Association Between High Triglyceride Levels and Increased Cardiovascular Events and Healthcare Costs in People with Diabetes Mellitus

    BEDMINSTER, N.J. and DUBLIN, Ireland, June 25, 2018-- Amarin Corporation plc, a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, ...

  • Is the Options Market Predicting a Spike in Amarin (AMRN) Stock?
    Zacks2 months ago

    Is the Options Market Predicting a Spike in Amarin (AMRN) Stock?

    Investors in Amarin (AMRN) need to pay close attention to the stock based on moves in the options market lately.

  • GlobeNewswire2 months ago

    Amarin and Mochida Announce Collaboration on Future Development of EPA-based Drug Products and Indications

    Amarin Corporation plc (AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that it has entered into a multi-faceted collaboration with Mochida Pharmaceutical Co., Ltd. (“Mochida”, TYO:4534), an integrated Japanese pharmaceutical company. The collaboration is focused on the development and commercialization of early-stage drug products and indications based on the omega-3 acid, EPA (eicosapentaenoic acid). Amarin and Mochida are recognized worldwide as the leading, innovation-driven companies committed to the research and development of EPA-based drug products to treat the needs of tens of millions of patients who are at-risk of cardiovascular disease.

  • GlobeNewswire2 months ago

    Amarin Sponsors Three Scientific Presentations Scheduled for American Diabetes Association Scientific Sessions

    BEDMINSTER, N.J. and DUBLIN, Ireland, June 07, 2018-- Amarin Corporation plc, a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, ...

  • GlobeNewswire2 months ago

    Research Report Identifies Diodes, Arbutus Biopharma, Radware, Immutep, Amarin, and SPS Commerce with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, June 06, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Diodes ...

  • ACCESSWIRE2 months ago

    Complimentary Technical Snapshots on Axovant Sciences and Three More Biotech Stocks

    LONDON, UK / ACCESSWIRE / June 4, 2018 / If you want a free Stock Review on AXON sign up now at www.wallstequities.com/registration. In today's pre-market research, WallStEquities.com scans Actinium Pharmaceuticals Inc. (NYSE AMER: ATNM), Amarin Corp. PLC (NASDAQ: AMRN), Apricus Biosciences Inc. (NASDAQ: APRI), and Axovant Sciences Ltd (NASDAQ: AXON).

  • Benzinga3 months ago

    Benzinga's Daily Biotech Pulse: Biomarin Gets FDA Nod, Amarin Settles with Teva, Merck's Cancer Drug Review Extended

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks Here are the biotech stocks that were hitting 52-week highs May 24:  ArQule, Inc. (NASDAQ: ARQL ) Baxter ...

  • GlobeNewswire3 months ago

    Amarin Announces Patent Litigation Settlement Agreement with Teva

    BEDMINSTER, N.J. and DUBLIN, Ireland, May 24, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today a settlement agreement with Teva Pharmaceuticals USA, Inc. (Teva) that resolves Amarin’s previously reported Vascepa® (icosapent ethyl) patent litigation as it relates to Teva’s abbreviated new drug application seeking U.S. Food and Drug Administration (FDA) approval of generic forms of Vascepa (icosapent ethyl) capsules. This patent litigation continues in the United States District Court for the District of Nevada with parties West-Ward Pharmaceuticals Corp. and Dr. Reddy’s Laboratories, Inc. and their affiliated entities.

  • GlobeNewswire3 months ago

    Amarin to Present at the Jefferies Global Healthcare Conference

    Amarin Corporation plc (AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's president and chief executive officer, is scheduled to present a general company update at the Jefferies Global Healthcare Conference in New York City on Thursday, June 7, 2018, at 8:00 a.m. EDT. Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health.  Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids.  Vascepa® (icosapent ethyl), Amarin's first FDA-approved product, is a highly-pure, omega-3 fatty acid product available by prescription.  For more information about Vascepa visit www.vascepa.com.  For more information about Amarin visit www.amarincorp.com.

  • Is the Options Market Predicting a Spike in Amarin (AMRN) Stock?
    Zacks3 months ago

    Is the Options Market Predicting a Spike in Amarin (AMRN) Stock?

    Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of AMRN earnings conference call or presentation 2-May-18 11:30am GMT

    Q1 2018 Amarin Corporation PLC Earnings Call

  • Associated Press4 months ago

    Amarin: 1Q Earnings Snapshot

    The Dublin-based company said it had a loss of 8 cents per share. Losses, adjusted for stock option expense, were 7 cents per share. The results met Wall Street expectations. The average estimate of three ...